{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:22:39Z","timestamp":1790504559776,"version":"4.1.0"},"reference-count":12,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2011,3,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Dasatinib is an orally available tyrosine kinase inhibitor with low nanomolar activity against SRC family kinases, BCR-ABL, c-KIT, EPHA2, and the PDGF-\u03b2 receptor. Dasatinib was found to have selective activity in several tumor models in the Pediatric Preclinical Testing Program. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> A phase I study of dasatinib in pediatric patients with refractory solid tumors or imatinib-refractory, Philadelphia chromosome\u2013positive leukemia was performed. Dose levels of 50, 65, 85, and 110 mg\/m<jats:sup>2<\/jats:sup>\/dose, administered orally twice daily for 28 days, with courses repeated without interruption, were studied. Pharmacokinetic studies were performed with the initial dose. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> A total of 39 patients (solid tumors, n = 28; chronic myeloid leukemia [CML], n = 9; acute lymphoblastic leukemia, n = 2) were enrolled. No dose-limiting toxicities (DLTs) were observed at the 50, 65, and 85 mg\/m<jats:sup>2<\/jats:sup> dose levels. At 110 mg\/m<jats:sup>2<\/jats:sup>, two of six patients experienced DLT including grade 2 diarrhea and headache. In children with leukemia, grade 4 hypokalemia (50 mg\/m<jats:sup>2<\/jats:sup>), grade 3 diarrhea (85 mg\/m<jats:sup>2<\/jats:sup>), and grade 2 creatinine elevation (50 mg\/m<jats:sup>2<\/jats:sup>) were observed. DLT in later courses included pleural effusions, hemangiomatosis, and GI hemorrhage. There were three complete cytogenetic responses, three partial cytogenetic responses, and two partial\/minimal cytogenetic responses observed in evaluable patients with CML. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Overall, drug disposition and tolerability of dasatinib were similar to those observed in adult patients. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2010.30.7231","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T06:21:06Z","timestamp":1295936466000},"page":"839-844","source":"Crossref","is-referenced-by-count":101,"title":["Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium"],"prefix":"10.1200","volume":"29","author":[{"given":"Richard","family":"Aplenc","sequence":"first","affiliation":[{"name":"From The Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine, Philadelphia, PA; Baylor College of Medicine, Houston, TX; Bristol-Meyers Squibb, Wallingford, CT; Dana-Farber Cancer Center; Harvard Medical School, Boston, MA; Children's Oncology Group Statistics and Data Center, Arcadia, CA; University of Nebraska Medical Center, Omaha, NE; and Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Blaney","sequence":"additional","affiliation":[{"name":"From The Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine, Philadelphia, PA; Baylor College of Medicine, Houston, TX; Bristol-Meyers Squibb, Wallingford, CT; Dana-Farber Cancer Center; Harvard Medical School, Boston, MA; Children's Oncology Group Statistics and Data Center, Arcadia, CA; University of Nebraska Medical Center, Omaha, NE; and Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis C.","family":"Strauss","sequence":"additional","affiliation":[{"name":"From The Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine, Philadelphia, PA; Baylor College of Medicine, Houston, TX; Bristol-Meyers Squibb, Wallingford, CT; Dana-Farber Cancer Center; Harvard Medical School, Boston, MA; Children's Oncology Group Statistics and Data Center, Arcadia, CA; University of Nebraska Medical Center, Omaha, NE; and Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Balis","sequence":"additional","affiliation":[{"name":"From The Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine, Philadelphia, PA; Baylor College of Medicine, Houston, TX; Bristol-Meyers Squibb, Wallingford, CT; Dana-Farber Cancer Center; Harvard Medical School, Boston, MA; Children's Oncology Group Statistics and Data Center, Arcadia, CA; University of Nebraska Medical Center, Omaha, NE; and Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Shusterman","sequence":"additional","affiliation":[{"name":"From The Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine, Philadelphia, PA; Baylor College of Medicine, Houston, TX; Bristol-Meyers Squibb, Wallingford, CT; Dana-Farber Cancer Center; Harvard Medical School, Boston, MA; Children's Oncology Group Statistics and Data Center, Arcadia, CA; University of Nebraska Medical Center, Omaha, NE; and Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Mark","family":"Ingle","sequence":"additional","affiliation":[{"name":"From The Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine, Philadelphia, PA; Baylor College of Medicine, Houston, TX; Bristol-Meyers Squibb, Wallingford, CT; Dana-Farber Cancer Center; Harvard Medical School, Boston, MA; Children's Oncology Group Statistics and Data Center, Arcadia, CA; University of Nebraska Medical Center, Omaha, NE; and Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Agrawal","sequence":"additional","affiliation":[{"name":"From The Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine, Philadelphia, PA; Baylor College of Medicine, Houston, TX; Bristol-Meyers Squibb, Wallingford, CT; Dana-Farber Cancer Center; Harvard Medical School, Boston, MA; Children's Oncology Group Statistics and Data Center, Arcadia, CA; University of Nebraska Medical Center, Omaha, NE; and Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Sun","sequence":"additional","affiliation":[{"name":"From The Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine, Philadelphia, PA; Baylor College of Medicine, Houston, TX; Bristol-Meyers Squibb, Wallingford, CT; Dana-Farber Cancer Center; Harvard Medical School, Boston, MA; Children's Oncology Group Statistics and Data Center, Arcadia, CA; University of Nebraska Medical Center, Omaha, NE; and Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[{"name":"From The Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine, Philadelphia, PA; Baylor College of Medicine, Houston, TX; Bristol-Meyers Squibb, Wallingford, CT; Dana-Farber Cancer Center; Harvard Medical School, Boston, MA; Children's Oncology Group Statistics and Data Center, Arcadia, CA; University of Nebraska Medical Center, Omaha, NE; and Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Adamson","sequence":"additional","affiliation":[{"name":"From The Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine, Philadelphia, PA; Baylor College of Medicine, Houston, TX; Bristol-Meyers Squibb, Wallingford, CT; Dana-Farber Cancer Center; Harvard Medical School, Boston, MA; Children's Oncology Group Statistics and Data Center, Arcadia, CA; University of Nebraska Medical Center, Omaha, NE; and Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23655"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21368"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046888"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0224"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.5599"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23238"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018267"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2010.30.7231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:29:51Z","timestamp":1653517791000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2010.30.7231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,3,1]]}},"alternative-id":["10.1200\/JCO.2010.30.7231"],"URL":"https:\/\/doi.org\/10.1200\/jco.2010.30.7231","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,1]]}}}